Get the Stockscreener App
2.63
5.40%
-0.15
Nls Pharmaceutics Ltd stock is traded at $2.63, with a volume of 155.27K.
It is down -5.40% in the last 24 hours and up +22.33% over the past month.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
See More
Previous Close:
$2.78
Open:
$2.8
24h Volume:
155.27K
Relative Volume:
0.50
Market Cap:
$9.46M
Revenue:
-
Net Income/Loss:
$-15.47M
P/E Ratio:
-5.26
EPS:
-0.5
Net Cash Flow:
$-13.51M
1W Performance:
+4.78%
1M Performance:
+22.33%
6M Performance:
+34.87%
1Y Performance:
-63.02%
1-Day Range:
$2.5601
$2.8032
1-Week Range:
$2.471
$2.8032
52-Week Range:
$1.30
$7.368
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Compare NLSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
2.63 | 12.66M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Nls Pharmaceutics Ltd Stock (NLSP) Latest News
Published on: 2025-08-20 15:01:54 - Newser
Will earnings trigger a reversal in NLS Pharmaceutics AGPortfolio Performance Report & High Return Trade Opportunity Guides - Newser
Tools to monitor NLS Pharmaceutics AG recovery probabilityEntry Point & High Return Trade Guides - Newser
Is this a good reentry point in NLS Pharmaceutics AG Equity WarrantQuarterly Profit Review & Long-Term Capital Growth Strategies - Newser
Does NLS Pharmaceutics AG fit your quant trading modelWeekly Trade Analysis & Risk Controlled Swing Alerts - Newser
Chart overlay techniques for tracking NLS Pharmaceutics AGProduct Launch & Reliable Entry Point Alerts - Newser
Analyzing NLS Pharmaceutics AG with multi timeframe chartsEarnings Overview Report & Accurate Technical Buy Alerts - Newser
NLS Pharmaceutics AG Equity Warrant Rebound Backed by Sentiment ShiftMarket Activity Recap & Precise Trade Entry Recommendations - metal.it
What makes NLS Pharmaceutics AG Equity Warrant stock price move sharplyEarnings Beat & Safe Entry Point Identification - sundaytimes.kr
What Technical Tools Say About NLS Pharmaceutics AG Recovery2025 Stock Rankings & Community Consensus Trade Signals - thegnnews.com
Published on: 2025-08-13 08:40:21 - Newser
How NLS Pharmaceutics AG stock performs during market volatility2025 Price Momentum & Short-Term Trading Alerts - Newser
How to escape a deep drawdown in NLS Pharmaceutics AGBreakout Stock Opportunities with Low Drawdown - Newser
What machine learning models say about NLS Pharmaceutics AG Equity WarrantBuy Zone Strategy with Pattern Recognition - Newser
How NLS Pharmaceutics AG stock reacts to Fed policy changesControlled Entry Strategy With Safety Analytics - Newser
NLS Pharmaceutics Regains Compliance With Nasdaq Stockholders' Equity Requirement - 富途牛牛
Using data models to predict NLS Pharmaceutics AG stock movementFree Entry Alert With Low Drawdown Strategy - Newser
Is NLS Pharmaceutics AG Equity Warrant still worth holding after the dipForecasting Stock Moves with AI Insights - Newser
Can technical indicators confirm NLS Pharmaceutics AG’s reversalRSI and MACD Signal Summary with Trends - Newser
Developing predictive dashboards with NLS Pharmaceutics AG Equity Warrant dataFree Weekly Setup With 3x Return Potential - Newser
Building trade automation scripts for NLS Pharmaceutics AGFree Smart Trade Plans With Risk Protection - Newser
Can trapped investors hope for a rebound in NLS Pharmaceutics AGWeekly Growth Portfolio Performance Summary - Newser
NLS Pharmaceutics Enters Warrant Exchange Agreement with Alpha Capital - TipRanks
Custom watchlist performance reports with NLS Pharmaceutics AGFree Fundamental Winners With Safe Entry Plan - Newser
Can momentum traders help lift NLS Pharmaceutics AG Equity WarrantLow Risk Stock Trade Opportunity Analysis - Newser
Volume spikes in NLS Pharmaceutics AG stock – what they meanTrend Confirmation Scanner with Entry Focus - Newser
Why NLS Pharmaceutics AG stock attracts strong analyst attentionFree Early Entry Tips With Low Risk Zone - Newser
Does NLS Pharmaceutics AG Equity Warrant stock pay reliable dividendsFree Stock Market Watch With Alerts - Newser
How many analysts rate NLS Pharmaceutics AG as a “Buy”Achieve fast wealth growth with smart picks - Jammu Links News
What are the latest earnings results for NLS Pharmaceutics AGMassive wealth growth - Jammu Links News
How does NLS Pharmaceutics AG compare to its industry peersSky-high profits - Jammu Links News
NLS Pharmaceutics Announces Merger with Kadimastem and Secures $25 Million Financing Facility - AInvest
How does NLS Pharmaceutics AG Equity Warrant generate profit in a changing economyDaily Trading Alerts For Every Investor - Jammu Links News
Is This the Dip to Buy in NLS Pharmaceutics AGChart Breakout Buy Signal Detection Confirmed - beatles.ru
Institutional scanner results for NLS Pharmaceutics AG Equity WarrantAI Trend Detection for Entry Timing - Newser
How strong is NLS Pharmaceutics AG company’s balance sheetMarket Forecast Outlook With Proven Results - Jammu Links News
NLS Pharmaceutics AG Inches Above Key Support — Safe to HoldMarket Surge Signal for Swing Traders Triggered - metal.it
Can technical indicators confirm NLS Pharmaceutics AG Equity Warrant’s reversal - Newser
Will NLS Pharmaceutics AG Equity Warrant stock recover after recent dropSwing Entry Risk Mitigation with Chart Analysis - Newser
NLS Pharmaceutics (NASDAQ:NLSP) Shares Up 2% – Should You Buy? - Defense World
Sector Leaders Rotate Capital Into NLS Pharmaceutics AGProfit Focused Stock Screener Results Released - metal.it
Published on: 2025-07-28 23:38:35 - metal.it
Risk vs reward if holding onto NLS Pharmaceutics AG Equity WarrantShort-Term Market Movement Forecast Report - Newser
Does NLS Pharmaceutics AG Equity Warrant stock perform well during market downturnsConsistently high yield - Jammu Links News
What is the dividend policy of NLS Pharmaceutics AG stockGet timely alerts on market opportunities - Jammu Links News
What is the risk reward ratio of investing in NLS Pharmaceutics AG Equity Warrant stockAI Powered Tracker That Work - jammulinksnews.com
Is it the right time to buy NLS Pharmaceutics AG stockUnlock exclusive trading strategies for gains - Jammu Links News
Should I hold or sell NLS Pharmaceutics AG Equity Warrant stock in 2025Get daily updates on the hottest stocks - jammulinksnews.com
Nls Pharmaceutics Ltd Stock (NLSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):